- • Up to 20% off your first purchase
- • Bulk quantities available
- • Citation Reward application
Sample Application
- Animal health test
- In-vitro diagnostics
- Food & Feed Safety
- Environmental Safety
- New drug discovery
Supports
- Talk to our Expert:
[email protected] -
Talk to our sales:
[email protected]
Protocol Library Download
 |
 |
Anti-CYP1A1 monoclonal antibody
Pre-made anti-CYP1A1 monoclonal antibody(mab)-benchmark antibody for ELISA, affinity binding assay, drug discovery and mechanism of action (MOA) research
Go to CYP1A1/CYP1A1 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)
MSDSProduct information
| Catalog No. | Product Name | Species Reactivity |
|---|---|---|
| GM-Tg-hg-IP0642-Ab-1/ GM-Tg-hg-IP0642-Ab-2 | Anti-Human CYP1A1 monoclonal antibody | Human |
| GM-Tg-rg-IP0642-Ab-1/ GM-Tg-rg-IP0642-Ab-2 | Anti-Rat CYP1A1 monoclonal antibody | Rat |
| GM-Tg-mg-IP0642-Ab-1/ GM-Tg-mg-IP0642-Ab-2 | Anti-Mouse CYP1A1 monoclonal antibody | Mouse |
| GM-Tg-cynog-IP0642-Ab-1/ GM-Tg-cynog-IP0642-Ab-2 | Anti-Cynomolgus/ Rhesus macaque CYP1A1 monoclonal antibody | Cynomolgus/ Rhesus macaque |
| GM-Tg-felg-IP0642-Ab-1/ GM-Tg-felg-IP0642-Ab-2 | Anti-Feline CYP1A1 monoclonal antibody | Feline |
| GM-Tg-cang-IP0642-Ab-1/ GM-Tg-cang-IP0642-Ab-2 | Anti-Canine CYP1A1 monoclonal antibody | Canine |
| GM-Tg-bovg-IP0642-Ab-1/ GM-Tg-bovg-IP0642-Ab-2 | Anti-Bovine CYP1A1 monoclonal antibody | Bovine |
| GM-Tg-equg-IP0642-Ab-1/ GM-Tg-equg-IP0642-Ab-2 | Anti-Equine CYP1A1 monoclonal antibody | Equine |
Size： 1mg | 10mg | 100mg
Product Description
| Catalog No. | GM-Tg-hg-IP0642-Ab-1/ GM-Tg-hg-IP0642-Ab-2; GM-Tg-rg-IP0642-Ab-1/ GM-Tg-rg-IP0642-Ab-2; GM-Tg-mg-IP0642-Ab-1/ GM-Tg-mg-IP0642-Ab-2; GM-Tg-cynog-IP0642-Ab-1/ GM-Tg-cynog-IP0642-Ab-2; GM-Tg-felg-IP0642-Ab-1/ GM-Tg-felg-IP0642-Ab-2; GM-Tg-cang-IP0642-Ab-1/ GM-Tg-cang-IP0642-Ab-2; GM-Tg-bovg-IP0642-Ab-1/ GM-Tg-bovg-IP0642-Ab-2; GM-Tg-equg-IP0642-Ab-1/ GM-Tg-equg-IP0642-Ab-2 |
| Products Name | Anti-CYP1A1 monoclonal antibody |
| Format | mab |
| Target Name | CYP1A1 |
| Protein Sub-location | Introcelluar Protein |
| Category of antibody | |
| Derivation (species) | Mouse |
| CH1+2+3 Isotype (Receptor identification) | IgG |
| Type of Light Chain (VD-LC) | N/A |
| Expression platform | Mammalian Expression |
| Bioactivity validation | Binding affinity is validated by ELISA with recombinant soluble protein antigen. The potency in neutralizing, inhibiting or blocking of the target protein is not detected. |
| Tag | Fc |
| Products description | Pre-made anti-CYP1A1 monoclonal antibody(mab) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) |
| Purity | Purity: ≥95% (SDS-PAGE) |
| Application | Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research. |
| Formulation & Reconstitution | Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4); For PSB2, reconstituted with 0.9% sodium chloride; For PBS, reconstituted with ddH2O. |
| Storage | Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles. |
Reference
Data / case study
Click to get more Data / Case study about the product.
Associated products
| Category | Cat No. | Products Name |
| Target Antigen | GM-Tg-g-IP0642-Ag-1 | Recombinant multi-species CP1A1/ CYP1A1/ AHH protein |
| ORF Viral Vector | vGMAP000197 | Human CYP1A1 Adenovirus particle |
| ORF Viral Vector | pGMAP000197 | Human CYP1A1 Adenovirus plasmid |
| ORF Viral Vector | pGMAD000068 | mouse Cyp1a1 Adenovirus plasmid |
| ORF Viral Vector | vGMAD000068 | mouse Cyp1a1 Adenovirus particle |
Target information
| Target ID | GM-IP0642 |
| Target Name | CYP1A1 |
| Gene ID | 1543,13076,554347,282870,100062285 |
| Gene Symbol and Synonyms | AHH,AHRR,CP11,CYP1,CYP1A1,CYP1A2,CYPIA1,P1-450,P450-1,P450-C,P450DX |
| Uniprot Accession | P04798,Q5KQT7 |
| Uniprot Entry Name | CP1A1_HUMAN,CP1A1_FELCA |
| Protein Sub-location | Introcelluar Protein |
| Category | |
| Disease | Cancer |
| Gene Ensembl | ENSG00000140465 |
| Target Classification | Tumor-associated antigen (TAA) |
The target: CYP1A1, gene name: CYP1A1, also named as AHH, AHRR, CP11, CYP1, CYPIA1, P1-450, P450-C, P450DX. This gene, CYP1A1, encodes a member of the cytochrome P450 superfamily of enzymes. The cytochrome P450 proteins are monooxygenases which catalyze many reactions involved in drug metabolism and synthesis of cholesterol, steroids and other lipids. This protein localizes to the endoplasmic reticulum and its expression is induced by some polycyclic aromatic hydrocarbons (PAHs), some of which are found in cigarette smoke. The enzyme's endogenous substrate is unknown; however, it is able to metabolize some PAHs to carcinogenic intermediates. The gene has been associated with lung cancer risk. A related family member, CYP1A2, is located approximately 25 kb away from CYP1A1 on chromosome 15. Alternative splicing results in multiple transcript variants encoding distinct isoforms. [provided by RefSeq, Jan 2016].
About Gmab
GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.
Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.
Facebook
LinkedIn
Twitter
